Study

A new study showed the success of an experimental vaccine developed by researchers at the American University of “Pavalo” to provide complete protection for experimental mice against the H5N1 2.3.4.4b breed, a dangerous breed of bird flu virus, which caused widespread outbreaks between wild birds and poultry, and also to livestock, and others. The vaccine depends on an innovative technique, called a copop vaccine platform, which has already undergone clinical trials as a possible vaccine against the Corona virus, which increases the chances of its success in combating advanced bird griepras. The new vaccine works in a clever way in two important parts of the bird flu virus, the first is known as “Hemaglinin” (H5), and the virus helps to stick to cells, and the second “Nromedas” (N1), which helps spread it. Bird flu vaccine and scientists made micro particles, thousands of often smaller than hair, and wore it with small pieces of these two virus parts. As you inject the vaccine, the body gets to know these viral parts, and practices to fight it, so that if the right virus is attacked, the body is ready to destroy it quickly. The researchers tested the effectiveness of an experimental vaccine against the 2.3.3.4b bird flu on mice with 3 different combinations. The first composition, which contains only H5 protein, showed an incredible effectiveness of a full protection rate (100%), as it prevented pathological symptoms completely, and maintained mouse weights, and no effect of the virus appeared in the lungs. The second composition included only N1 protein, and it achieved a partial protection of 70% with the occurrence of some symptoms, while the third composition that brought H5 and N1 achieved complete protection, but without reaching the effectiveness of H5 alone, suggesting that the H5 protein that works as a ‘key’ is most important to reject the immune to the N1 protein – The virus. Reducing the symptoms of flu, and despite this, the researchers emphasized that the presence of N1 remains important to reduce the severity of the symptoms and the spread of the virus, especially with the development of new viral breeds. The new vaccine has benefits that make it better than traditional vaccines; It does not need eggs in its manufacture, as opposed to the current vaccines that need to be prepared in chicken eggs for weeks, making it faster production, and less vulnerable to pollution. It can be easily adapted to confront any new strains that occur from the virus, and the stimulants added increase the power of immune response, and most importantly, the technology used in the new vaccine was successful in the experiences of Corona vaccines, which give them credibility and prove their effectiveness. The researchers said that these properties make the new vaccine a strong candidate to be the perfect vaccine to confront bird flu. This vaccine is currently very important with the increasing spread of the severe H5N1 2.3.4b between birds and animals, and the beginning of separate human injuries. The new vaccine is an important tool that can stop the development of the virus in more dangerous forms, which can protect workers in the poultry and livestock sectors, which are most vulnerable to infection, as well as to quickly enable health authorities to address any new outbreaks. Although the road is still long for the production of the vaccine, the lead author of the study Jonathan Loville confirms that the initial results are optimistic and new horizons are open to developing more effective vaccines against these global health threats.